Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Early-phase drug discovery of β-III-spectrin actin-binding modulators for treatment of spinocerebellar ataxia type 5

Journal of Biological Chemistry(2023)10.1016/j.jbc.2023.102956Source: DataRank Database

Early-phase drug discovery of β-III-spectrin actin-binding modulators for treatment of spinocerebellar ataxia type 5 is a research paper published in Journal of Biological Chemistry (2023). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

Linked data & code

gen pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)OA: goldTopics (14)IDs (PubMed, PMC)Annotations (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Robyn T. Rebbeck ORCID,Sarah A. Denha,Amanda R. Keller,Anna L. Carter,Alexandra E. Atang ORCID

Live enrichment

PubMed:36731793 PMC:PMC9978034

National Institutes of Health

Grant: R37AG026160

National Institutes of Health

Grant: R01HL139065

National Institutes of Health

Grant: R01GM044757

National Institutes of Health

Grant: R15NS116511

National Institutes of Health

Grant: R61NS111075

National Institutes of Health

Grant: GM027906

NINDS NIH HHS

Grant: R33 NS111075

NIGMS NIH HHS

Grant: R01 GM027906

NIH HHS

Grant: R24 OD034063

goldLicense: cc-by

publisherhttp://www.jbc.org/article/S0021925823000881/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0021925823000881?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0021925823000881?httpAccept=text/plain

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC9978034/pdf/main.pdf

Europe_PMChttps://europepmc.org/articles/PMC9978034

MeSH Terms

NeuronsHumansSpinocerebellar AtaxiasActinsSpectrinDrug Discovery

Keywords

Drug screeningFluorescence lifetimeSpinocerebellar ataxiaTime-resolved FretActin BindingSca5Swinholide AΒ-iii-spectrin

Early-phase drug discovery of β-III-spectrin actin-binding modulators for treatment of spinocerebellar ataxia type 5

FAIR Checklist

Authors (10)

Funding (9 grants)

Open Access

Topics

Annotations (Europe PMC)